Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.66 |
| ▸ | CA9 | Q16790 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180384 | 0.85 | NPC1 (0.73) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL3095761 | 0.83 | NPC1 (0.70) | NPC1RAB9ACA12CA9KMT2A | |
| Hydrochloric Acid SCHEMBL11786759 | 0.83 | NPC1 (0.70) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL967363 | 0.81 | NPC1 (0.68) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL425164 | 0.81 | NPC1 (0.68) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL30957107 | 0.80 | CA12 (0.67) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL991685 | 0.80 | RAB9A (0.72) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL5647434 | 0.80 | TAAR1 (0.55) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL12039097 | 0.80 | RIPK1 (0.58) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL3396666 | 0.80 | NPC1 (0.56) | NPC1RAB9ACA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| US-12378204-B2 | Triazole compounds and preparation method therefor and use thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| CN-114478336-B | Process for producing mercaptophenol compound and intermediate therefor | 组合化学工业株式会社 | 2024-05-14 | — | — | CN | disclosed |
| EP-4294798-A1 | FACTOR XIIA INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| CN-116829547-A | Factor XIIa inhibitors | 卡尔维斯塔制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-4739106-A | VASODILATION, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0101023-B1 | PROCESS FOR PREPARING 2-CARBAMOYLOXYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND INTERMEDIATES USEFUL FOR THE PROCESS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-07-29 | — | — | EP | disclosed |
| EP-0056637-B1 | 4(3H)-QUINAZOLINONE DERIVATIVES, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | Ishikawa, Masayuki (JP) | 1985-07-24 | — | — | EP | disclosed |
| US-4451467-A | HYPOTENSIVE AGENTS | Ishikawa, Masayuki (JP) | 1984-05-29 | — | — | US | disclosed |
| EP-0101023-A1 | Process for preparing 2-carbamoyloxyalkyl-1,4-dihydropyridine derivatives and intermediates useful for the process | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1984-02-22 | — | — | EP | disclosed |
| EP-0056637-A1 | 4(3H)-quinazolinone derivatives, process for production thereof and pharmaceutical compositions comprising said compounds | Ishikawa, Masayuki (JP) | 1982-07-28 | — | — | EP | disclosed |
| US-4340416-A | HERBICIDES | MONSANTO COMPANY (US) | 1982-07-20 | — | — | US | disclosed |
| US-4261727-A | POSTEMERGENT ACTIVITY | MONSANTO COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
| US-4163112-A | INSECTICIDES | VELSICOL CHEMICAL CORPORATION (US) | 1979-07-31 | — | — | US | disclosed |
| US-3974140-A | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | NPC1 2492/4885RAB9A 1856/4885CA12 965/4885 |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | NPC1 3064/4885RAB9A 2183/4885CA12 922/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | NPC1 132/4885RAB9A 967/4885CA12 80/4885 |
| US-12378204-B2 | Triazole compounds and preparation method therefor and use thereof | LPAR1, LPAR3, FFAR1 | NPC1 433/4885RAB9A 1891/4885CA12 4883/4885 |
| US-11732005-B2 | Peptidomimetic proteasome inhibitors | PSMB1, PSMB3, PSMB11 | NPC1 4075/4885RAB9A 2326/4885CA12 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.